BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 25297324)

  • 21. Analytical performance of the Investigational Use Only Cervista HPV HR test as determined by a multi-center study.
    Day SP; Hudson A; Mast A; Sander T; Curtis M; Olson S; Chehak L; Quigley N; Ledford J; Yen-Lieberman B; Kohn D; Quigley DI; Olson M
    J Clin Virol; 2009 Jul; 45 Suppl 1():S63-72. PubMed ID: 19651371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A parallel study of careHPV and Hybrid Capture 2 human papillomavirus DNA testing for cervical cancer screening in rural China.
    Lin CQ; Chen F; Liu B; Zhang YZ; Cui XL; Li AM; Zhang WH; Chen W; Chang I; Sivasubramaniam P; Zhu J; Qiao YL
    J Virol Methods; 2014 Jun; 202():73-8. PubMed ID: 24642241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) study.
    Gillio-Tos A; De Marco L; Carozzi FM; Del Mistro A; Girlando S; Burroni E; Frayle-Salamanca H; Giorgi Rossi P; Pierotti P; Ronco G;
    J Clin Microbiol; 2013 Sep; 51(9):2901-7. PubMed ID: 23804385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?
    Fokom Domgue J; Schiffman M; Wentzensen NH; Gage JC; Castle PE; Raine-Bennett TR; Fetterman B; Lorey T; Poitras NE; Befano B; Xie Y; Miachon LS; Dean M
    J Clin Microbiol; 2017 Aug; 55(8):2348-2355. PubMed ID: 28515214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
    Oštrbenk A; Xu L; Arbyn M; Poljak M
    J Clin Microbiol; 2018 Nov; 56(11):. PubMed ID: 30209184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the PANArray HPV Genotyping Chip Test with the Cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of HPV in ASCUS Women.
    Ki EY; Lee YK; Lee A; Park JS
    Yonsei Med J; 2018 Jul; 59(5):662-668. PubMed ID: 29869464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the PapilloCheck DNA micro-array Human Papillomavirus detection assay with Hybrid Capture II and PCR-enzyme immunoassay using the GP5/6+ primer set.
    Jones J; Powell NG; Tristram A; Fiander AN; Hibbitts S
    J Clin Virol; 2009 Jun; 45(2):100-4. PubMed ID: 19394266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
    Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
    BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Xpert human papillomavirus test is a promising cervical cancer screening test for HIV-seropositive women.
    Mbulawa ZZA; Wilkin TJ; Goeieman B; Swarts A; Williams S; Levin S; Faesen M; Smith JS; Chibwesha CJ; Williamson AL; Firnhaber C
    Papillomavirus Res; 2016 Dec; 2():56-60. PubMed ID: 29074186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
    Polman NJ; Oštrbenk A; Xu L; Snijders PJF; Meijer CJLM; Poljak M; Heideman DAM; Arbyn M
    J Clin Microbiol; 2017 Dec; 55(12):3544-3551. PubMed ID: 29021152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of analytical and clinical performances of the digene HC2 HPV DNA assay and the INNO-LiPA HPV genotyping assay for detecting high-risk HPV infection and cervical neoplasia among HIV-positive African women.
    Ngou J; Gilham C; Omar T; Goumbri-Lompo O; Doutre S; Michelow P; Kelly H; Didelot MN; Chikandiwa A; Sawadogo B; Delany-Moretlwe S; Meda N; Costes V; Mayaud P; Segondy M
    J Acquir Immune Defic Syndr; 2015 Feb; 68(2):162-8. PubMed ID: 25394189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantivirus® HPV E6/E7 RNA 3.0 assay (bDNA) is as sensitive, but less specific than Hybrid Capture 2 test.
    Shen Y; Gong J; He Y; Cheng G; Okunieff P; Li X
    J Virol Methods; 2013 Feb; 187(2):288-93. PubMed ID: 23201290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of GeneFinder human papillomavirus (HPV) Liquid Beads Microarray PCR Kit and Hybrid Capture 2 Assay for Detection of HPV Infection.
    Ko K; Kwon MJ; Lee EH; Woo HY; Park H
    J Clin Lab Anal; 2017 Mar; 31(2):. PubMed ID: 27387091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Laboratory diagnosis of human papillomavirus infection.
    Ikenberg H
    Curr Probl Dermatol; 2014; 45():166-74. PubMed ID: 24643185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HPV testing for cervical cancer screening: technical improvement of laboratory logistics and good clinical performance of the cobas 6800 in comparison to the 4800 system.
    Frayle H; Gori S; Rizzi M; Graziani BN; Vian E; Giorgi Rossi P; Del Mistro A
    BMC Womens Health; 2019 Mar; 19(1):47. PubMed ID: 30909894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the performance of Anyplex II HPV HR, the Cobas 4800 human papillomavirus test and Hybrid Capture 2.
    Lee DH; Hwang NR; Lim MC; Yoo CW; Joo J; Kim JY; Park SY; Hwang SH
    Ann Clin Biochem; 2016 Sep; 53(Pt 5):561-7. PubMed ID: 26486441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison between the Hybrid Capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low grade dysplasia.
    Gustavsson I; Juko-Pecirep I; Backlund I; Wilander E; Gyllensten U
    J Clin Virol; 2009 Jun; 45(2):85-9. PubMed ID: 19451022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study.
    Rao A; Sandri MT; Sideri M; Young S; Sharma A; Behrens C
    J Clin Virol; 2013 Sep; 58(1):161-7. PubMed ID: 23895930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative evaluation of three commercial systems for detection of high-risk human papillomavirus in cervical and vaginal ThinPrep PreservCyt samples and correlation with biopsy results.
    Binnicker MJ; Pritt BS; Duresko BJ; Espy MJ; Grys TE; Zarka MA; Kerr SE; Henry MR
    J Clin Microbiol; 2014 Oct; 52(10):3763-8. PubMed ID: 25122861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of oncogenic HPV type-specific viral DNA load and E6/E7 mRNA detection in cervical samples: results from a multicenter study.
    Broccolo F; Fusetti L; Rosini S; Caraceni D; Zappacosta R; Ciccocioppo L; Matteoli B; Halfon P; Malnati MS; Ceccherini-Nelli L
    J Med Virol; 2013 Mar; 85(3):472-82. PubMed ID: 23280876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.